{
    "1": {
        "question": "What was the primary aim of the cohort study on COVID-19 vaccination and cardiovascular safety?",
        "options": {
            "A": "To compare the effects of different vaccine doses on general population mortality.",
            "B": "To evaluate the risk of cardiovascular complications after second and booster COVID-19 vaccine doses.",
            "C": "To investigate the respiratory benefits of COVID-19 vaccines.",
            "D": "To assess the efficacy of COVID-19 vaccines against viral mutations.",
            "E": "To analyze the effects of vaccinations on neurological complications.",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "How many adults formed the study cohort in the analysis?",
        "options": {
            "A": "36.7 million",
            "B": "45.7 million",
            "C": "50.3 million",
            "D": "39.2 million",
            "E": "43.1 million",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "What was the main finding regarding the incidence of arterial thrombotic events after vaccination?",
        "options": {
            "A": "The incidence increased after vaccination.",
            "B": "The incidence remained unchanged.",
            "C": "The incidence was generally lower after each dose.",
            "D": "The incidence was only reduced after the first dose.",
            "E": "The incidence was only reduced after mRNA boosters.",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "Which COVID-19 vaccine brand was associated with vaccine-induced thrombotic thrombocytopenia?",
        "options": {
            "A": "BNT-162b2",
            "B": "mRNA-1273",
            "C": "ChAdOx1",
            "D": "All of the above",
            "E": "None of the above",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "What was the primary data source for this study on cardiovascular safety?",
        "options": {
            "A": "Patient questionnaires",
            "B": "Clinical trials",
            "C": "Electronic health records from NHS England",
            "D": "World Health Organization reports",
            "E": "Pharmaceutical company logs",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "Which thrombotic event was notably higher immediately after the first dose of ChAdOx1?",
        "options": {
            "A": "Pulmonary embolism",
            "B": "Ischaemic stroke",
            "C": "Intracranial venous thrombosis (ICVT)",
            "D": "Deep venous thrombosis",
            "E": "Subarachnoid haemorrhage",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "What statistical model was used to estimate hazard ratios in this study?",
        "options": {
            "A": "Linear regression",
            "B": "Cox regression",
            "C": "Logistic regression",
            "D": "Bayesian analysis",
            "E": "Factor analysis",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "Which age group showed the least reduction in arterial thrombotic event hazards after the first dose?",
        "options": {
            "A": "18-29 years old",
            "B": "30-39 years old",
            "C": "40-49 years old",
            "D": "50-59 years old",
            "E": "60-69 years old",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "What was the incidence trend of venous thrombotic events after COVID-19 vaccination?",
        "options": {
            "A": "Higher after first dose",
            "B": "Lower after each dose",
            "C": "Higher after booster doses",
            "D": "No change after vaccinations",
            "E": "Only lower after mRNA vaccinations",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "What was the aHR for arterial thrombotic events 13-24 weeks after the first ChAdOx1 dose?",
        "options": {
            "A": "1.50",
            "B": "0.99",
            "C": "0.75",
            "D": "1.25",
            "E": "0.85",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "What impact does the study suggest COVID-19 vaccination has on venous event reduction compared to non-vaccination?",
        "options": {
            "A": "No impact",
            "B": "Increased risk",
            "C": "Decreased risk",
            "D": "Impact only with booster doses",
            "E": "Impact only with mRNA vaccines",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "What was a unique finding regarding myocarditis in relation to mRNA booster vaccinations?",
        "options": {
            "A": "Decreased incidence after BNT-162b2",
            "B": "Increased incidence after mRNA-1273",
            "C": "Increased incidence following BNT-162b2 booster",
            "D": "No change after any booster",
            "E": "Decreased incidence after ChAdOx1 booster",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "Which population subgroup was associated with higher aHRs for composite arterial events?",
        "options": {
            "A": "People under age 30",
            "B": "People with known ethnicity",
            "C": "People with unknown ethnicity",
            "D": "Females",
            "E": "People without prior comorbidities",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "What was observed about the incidence of pericarditis after mRNA booster vaccinations?",
        "options": {
            "A": "Increased incidence only in females",
            "B": "Similar to or lower than before vaccination",
            "C": "Higher than before vaccination",
            "D": "No significant changes observed",
            "E": "Increased only with the primary ChAdOx1 course",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "How does the study characterize the cardiovascular profile following COVID-19 vaccination at the population level?",
        "options": {
            "A": "No cardiovascular changes post vaccination",
            "B": "Increased risk of heart attacks",
            "C": "Lower incidence of common events, but recognized rare harms",
            "D": "Unexplored effects on cardiovascular profile",
            "E": "Reduced risk of all cardiovascular events",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "What limitation does the study acknowledge in determining long-term vaccine safety?",
        "options": {
            "A": "Lack of long-term follow-up data",
            "B": "Inability to measure biological markers",
            "C": "Exclusion of elderly participants",
            "D": "Lack of variance in vaccine brands",
            "E": "Absence of control groups",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "After which vaccination dose was there a halving in pericarditis incidence beyond 4 weeks?",
        "options": {
            "A": "First dose of ChAdOx1",
            "B": "First dose of mRNA-1273",
            "C": "Second dose of ChAdOx1",
            "D": "Second dose of mRNA-1273",
            "E": "Booster dose of BNT-162b2",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "Which report did the study reference in regards to myocarditis and pericarditis public awareness?",
        "options": {
            "A": "The Lancet on Vaccine Side-Effects",
            "B": "World Health Organization Health Advisory",
            "C": "CDC public announcement",
            "D": "Nature COVID-19 Vaccine Article",
            "E": "British Medical Journal Editorial",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "What advantage does the study claim about its population data?",
        "options": {
            "A": "Exclusivity to Asian demographics",
            "B": "Greater detailed individual case studies",
            "C": "Representative whole-population insight",
            "D": "Specific insights into rural health",
            "E": "Focus on long-term consequences",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "Which vaccine group had the highest recorded aHR for intracranial venous thrombosis shortly post-vaccination?",
        "options": {
            "A": "First dose of mRNA-1273",
            "B": "First dose of BNT-162b2",
            "C": "First dose of ChAdOx1",
            "D": "Second dose of mRNA-1273",
            "E": "Booster dose of BNT-162b2",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "What was the study's conclusion about the overall cardiovascular safety of the COVID-19 vaccine?",
        "options": {
            "A": "The vaccine increases risk of cardiovascular events.",
            "B": "There are no known cardiovascular benefits.",
            "C": "Lower incidence of common cardiovascular events outweighs known rare complications.",
            "D": "The impact varies greatly by geographic location.",
            "E": "The vaccine's effects are inconclusive.",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "Which method was used to address potential sampling bias in the study?",
        "options": {
            "A": "Case-control study design",
            "B": "Randomized clinical trials",
            "C": "Inverse probability weighting",
            "D": "Placebo-controlled trials",
            "E": "Matching by demographic characteristics",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "What was a key finding regarding thrombotic events in males compared to females?",
        "options": {
            "A": "Higher in females than males post-vaccination.",
            "B": "Higher aHRs for males across multiple doses.",
            "C": "Similar across both sexes.",
            "D": "Indeterminate due to lack of data.",
            "E": "Only males experienced increased risks.",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "Which ethnic group was associated with higher aHRs for events after receiving the first dose of ChAdOx1?",
        "options": {
            "A": "Black ethnic group",
            "B": "Asian ethnic group",
            "C": "White ethnic group",
            "D": "Mixed ethnic group",
            "E": "Unknown ethnic group",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "What was the highest aHR for thrombocytopenia observed after any ChAdOx1 dose?",
        "options": {
            "A": "2.07",
            "B": "1.34",
            "C": "3.21",
            "D": "0.98",
            "E": "1.67",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "Which condition showed no increase in incidence after the second ChAdOx1 dose?",
        "options": {
            "A": "Intracranial venous thrombosis",
            "B": "Myocarditis",
            "C": "Pericarditis",
            "D": "Thrombocytopenia",
            "E": "Ischaemic stroke",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "How were hazard ratios for vaccine doses calculated in this study?",
        "options": {
            "A": "Using unmatched case-control studies",
            "B": "By comparing confounded groups directly",
            "C": "Utilizing adjusted Cox regression models",
            "D": "With machine learning algorithms",
            "E": "Via simple cohort comparisons",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "What factor primarily contributed to imprecise estimation of aHRs for mRNA-1273?",
        "options": {
            "A": "Lack of vaccine availability",
            "B": "Younger recipient age and fewer recipients",
            "C": "High variance in efficacy rates",
            "D": "Delayed vaccine approval",
            "E": "Mixed dosage batches",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "During which time period were the highest incidences of adverse cardiovascular outcomes observed?",
        "options": {
            "A": "13-24 weeks post-booster dose",
            "B": "1 week after second dose",
            "C": "5\u201324 weeks after first dose",
            "D": "Immediately 2 weeks after first dose",
            "E": "5 weeks after booster dose",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "What specific combination of vaccine doses showed reduced mesenteric thrombus incidence beyond 4 weeks?",
        "options": {
            "A": "Second dose of mRNA-1273",
            "B": "Second dose of ChAdOx1",
            "C": "First dose of BNT-162b2",
            "D": "Booster dose of BNT-162b2",
            "E": "Booster dose of mRNA-1273",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "What did subgroup analyses reveal about thrombotic events in confirmed COVID-19 history participants?",
        "options": {
            "A": "No differences observed",
            "B": "They had a lower aHR across vaccinations",
            "C": "They had a higher aHR post-first dose",
            "D": "Variable effects depending on vaccine brand",
            "E": "Reduced efficacy in known thrombosis history",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "How many arterial thrombotic events occurred during the study's observation without vaccination?",
        "options": {
            "A": "21,230",
            "B": "75,655",
            "C": "37,915",
            "D": "11,835",
            "E": "9,075",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "What method was employed to address outcome identification possibly influenced by public announcements?",
        "options": {
            "A": "Government notifications",
            "B": "Sensitivity analyses with event censoring",
            "C": "Community surveys",
            "D": "Focused group studies",
            "E": "Regression analyses",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "What was one limitation mentioned regarding outcome underreporting?",
        "options": {
            "A": "Events from rural areas were underrepresented",
            "B": "Non-English speakers were excluded",
            "C": "Diagnostic challenges in severe health cases",
            "D": "Limited number of reported side effects",
            "E": "Vaccine distribution was delayed",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "What was a finding from the SCCS studies related to COVID-19 vaccination?",
        "options": {
            "A": "COVID-19 vaccines have no cardiovascular effects",
            "B": "They provide preventive cardioprotective effects",
            "C": "Results align and can be triangulated with cohort findings",
            "D": "No statistically valid conclusions were drawn",
            "E": "Unique adverse effects unrelated to cohort findings",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "What covariate adjustments were made in all models for estimating hazard ratios?",
        "options": {
            "A": "Adjusted for gender and marital status",
            "B": "Adjusted for economic status alone",
            "C": "Adjusted for a comprehensive range of confounders",
            "D": "Adjusted exclusively based on geographic location",
            "E": "No adjustments were made",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "Which outcome had the highest hazard ratio a week after receiving the first dose of BNT-162b2?",
        "options": {
            "A": "Subarachnoid haemorrhage",
            "B": "Myocarditis",
            "C": "Ischaemic stroke",
            "D": "Deep venous thrombosis",
            "E": "Pericarditis",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "What determined the eligibility for booster dose analysis in the study?",
        "options": {
            "A": "Receiving any COVID-19 vaccine",
            "B": "Having completed the primary vaccine course",
            "C": "Specific occupation in healthcare",
            "D": "A history of heart disease",
            "E": "Geographical living location",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "Which vaccine brand was associated with the lowest incidence of arterial thrombotic events post-vaccination?",
        "options": {
            "A": "First dose of BNT-162b2",
            "B": "Second dose of mRNA-1273",
            "C": "Booster dose of ChAdOx1",
            "D": "Second dose of mRNA-1273",
            "E": "Booster dose of mRNA-1273",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "How does the study describe the effects of booster doses compared to the primary course?",
        "options": {
            "A": "Booster doses offer no additional cardiovascular benefits.",
            "B": "The incidence of complications remains unchanged.",
            "C": "They show a greater reduction in thrombotic events than the primary course.",
            "D": "They increase the risk of cardiovascular events.",
            "E": "They are necessary only for vulnerable populations.",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "Which key figure shows data related to myocarditis incidence based on vaccination?",
        "options": {
            "A": "Table 1",
            "B": "Table 2",
            "C": "Fig. 1",
            "D": "Fig. 3",
            "E": "Fig. 2",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "What type of patient data was excluded to maintain the study's focus?",
        "options": {
            "A": "Outpatient medical records",
            "B": "Patients vaccinated before Dec 8th 2020",
            "C": "Patients with no prior health issues",
            "D": "Records of patients over 80 years old",
            "E": "Data from private healthcare sectors",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "Which group received priority for BNT-162b2 or mRNA-1273 vaccine brands?",
        "options": {
            "A": "People over 65 years old",
            "B": "People under 40 years and not in priority groups",
            "C": "All frontline healthcare workers",
            "D": "Individuals with pre-existing cardiovascular conditions",
            "E": "Pregnant women",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "What differentiation was highlighted in populations receiving their second and booster doses?",
        "options": {
            "A": "Younger age distribution than first dose cohort",
            "B": "More ethnically diverse than first dose cohort",
            "C": "Older and less likely to have a non-White ethnicity",
            "D": "Substantial increased socioeconomic status",
            "E": "Primarily concentrated in urban areas",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "What was the estimated aHR for composite arterial events 13-24 weeks after a mRNA booster given both primary courses of BNT-162b2?",
        "options": {
            "A": "0.73",
            "B": "1.21",
            "C": "0.56",
            "D": "0.67",
            "E": "1.65",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "How were the primary analyses conducted concerning analysis datasets?",
        "options": {
            "A": "Focusing only on demographics",
            "B": "Including all known COVID-19 cases",
            "C": "Using random subsamples with balanced cases",
            "D": "Adapting datasets based on geographic origin",
            "E": "Only considering individuals over 50 years",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "How does the study assess subgroup associations with thrombotic events?",
        "options": {
            "A": "By focusing on individual case studies",
            "B": "Via broad association with demographic data",
            "C": "Through unique associations in single violence groups",
            "D": "Using standardized scales applicable to all groups",
            "E": "Very narrowly with no exceptions noted",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "What was often the focus in limitations about outcome event DB systems?",
        "options": {
            "A": "An inability to log duplicate events",
            "B": "Incomplete electronic health records",
            "C": "Details misreported on vaccination cards",
            "D": "Temporal data shifts due to regulatory changes",
            "E": "Day-of-week discrepancies",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "What reported trend was observed in regards to hospitalization-linked thrombotic events?",
        "options": {
            "A": "Masking of significant events due to data overlap",
            "B": "Underreporting of hospitalization cases",
            "C": "Rare thrombotic events commonly expected",
            "D": "Truthful in revelations akin to electronic health records",
            "E": "Highly variable when split by demographic data",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "What role did GitHub play in the study's analyses?",
        "options": {
            "A": "To host collaborative coding sessions",
            "B": "Distribution of an pre-specified protocol and code lists",
            "C": "Store de-identified population health records",
            "D": "Provide real-time updates during live trials",
            "E": "Centralize adverse event reporting",
            "F": "I don't know"
        }
    }
}